Shire Human Genetic Therapies Signs Exclusive Marketing and Distribution Deal With Samaritan Pharmaceuticals, Inc. to Launch REPLAGAL for Fabry Disease in Greece and Cyprus

LAS VEGAS, May 22, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, is pleased to announce it has signed a second exclusive marketing and distribution agreement, with Shire Human Genetic Therapies AB to launch and sell REPLAGAL(r) (agalsidase alfa), a European approved drug, for Fabry Disease, in Greece and Cyprus.

MORE ON THIS TOPIC